Dr. Grimberg investigates the growth hormone (GH)/insulin-like growth factor (IGF)-I axis and clinical issues related to child growth. Her recent research is focused on disparities in, and the decision-making related to, the medical management of children with short stature. She is fascinated by how differential societal pressures for tallness and the advent of an expensive therapeutic have transformed a fundamental aspect of pediatric healthcare.
Despite an FDA approval of growth hormone treatment for children with idiopathic short stature (ISS), the mean cost burden to patients and their families has increased over time, according to findings from researchers at Children’s Hospital of Philadelphia (CHOP) and the Leonard Davis Institute of Health Economics (LDI) of the University of Pennsylvania.
We've had a flurry of activity this week at Children's Hospital of Philadelphia Research Institute, including our first snowstorm of the year. In between shoveling, we took a few minutes to dig into the latest research news.
Physician-researchers from the Cardiac Center at Children's Hospital of Philadelphia (CHOP) presented new findings on pediatric cardiovascular disease at the American Heart Association's Scientific Sessions 2016 in New Orleans.
Children who are born with complex heart defects like congenital heart disease can often have poor growth. A new study from a pediatric cardiologist and her team at The Children's Hospital of Philadelphia suggests that that this poor growth may stem from factors beyond deficient nutrition, and may include abnormalities in overall growth regulation.
Providing comprehensive evaluation and treatment for children and adolescents with disorders of growth and puberty, and initiating research activities into the causes of growth-related conditions and quality of life issues.